% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Farooq:286593,
      author       = {M. Farooq and G. Scalia and G. E. Umana and U. Parekh$^*$
                      and F. Naeem and S. F. Abid and M. H. Khan and S. G. Zahra
                      and H. P. Sarkar and B. Chaurasia},
      title        = {{A} {S}ystematic {R}eview of {N}anomedicine in
                      {G}lioblastoma {T}reatment: {C}linical {E}fficacy, {S}afety,
                      and {F}uture {D}irections.},
      journal      = {Brain Sciences},
      volume       = {13},
      number       = {12},
      issn         = {2076-3425},
      address      = {Basel},
      publisher    = {MDPI AG},
      reportid     = {DKFZ-2023-02810},
      pages        = {1727},
      year         = {2023},
      abstract     = {(1) Background: Glioblastoma (GBM) is categorized as a
                      grade IV astrocytoma by the World Health Organization (WHO),
                      representing the most aggressive and prevalent form of
                      glioma. It presents a significant clinical challenge, with
                      limited treatment options and poor prognosis. This
                      systematic review evaluates the efficacy and safety of
                      various nanotherapy approaches for GBM and explores future
                      directions in tumor management. Nanomedicine, which involves
                      nanoparticles in the 1-100 nm range, shows promise in
                      improving drug delivery and targeting tumor cells. (2)
                      Methods: Following PRISMA guidelines, a systematic search of
                      databases including Google Scholar, NCBI PubMed, Cochrane
                      Library, and ClinicalTrials.gov was conducted to identify
                      clinical trials on GBM and nanomedicine. The primary outcome
                      measures were median overall survival, progression-free
                      survival, and quality of life assessed through Karnofsky
                      performance scores. The safety profile was assessed by
                      adverse events. (3) Results: The analysis included 225 GBM
                      patients, divided into primary and recurrent
                      sub-populations. Primary GBM patients had a median overall
                      survival of 6.75 months, while recurrent GBM patients had a
                      median overall survival of 9.7 months. The mean PFS period
                      was 2.3 months and 3.92 months in primary GBM and recurrent
                      GBM patients, respectively. Nanotherapy showed an
                      improvement in quality of life, with KPS scores increasing
                      after treatment in recurrent GBM patients. Adverse events
                      were observed in $14.2\%$ of patients. Notably, Bevacizumab
                      therapy exhibited better survival outcomes but with a higher
                      incidence of adverse events. (4) Conclusions: Nanotherapy
                      offers a modest increase in survival with fewer severe side
                      effects. It shows promise in improving the quality of life,
                      especially in recurrent GBM patients. However, it falls
                      short in terms of overall survival compared to Bevacizumab.
                      The heterogeneous nature of treatment protocols and
                      reporting methods highlights the need for standardized
                      multicenter trials to further evaluate the potential of
                      nanomedicine in GBM management.},
      subtyp        = {Review Article},
      keywords     = {glioblastoma (Other) / molecular markers (Other) /
                      nanomedicine (Other) / nanoparticles (Other) / quality of
                      life (Other) / theranostics (Other)},
      cin          = {B420},
      ddc          = {570},
      cid          = {I:(DE-He78)B420-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38137175},
      pmc          = {pmc:PMC10742051},
      doi          = {10.3390/brainsci13121727},
      url          = {https://inrepo02.dkfz.de/record/286593},
}